An Improved Selective Culture Medium Enhances the Isolation of *Burkholderia pseudomallei* from Contaminated Specimens

Andrew Goodyear, Linda Strange, Drew A. Rholl, Joy Silisouk, David A. B. Dance, Herbert P. Schweizer, and Steven Dow*

Department of Microbiology, Immunology, and Pathology, Rocky Mountain Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research, Colorado State University, Fort Collins, Colorado; Department of Biology, North Park University, Chicago, Illinois; Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao People’s Democratic Republic; Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom

Abstract. *Burkholderia pseudomallei* is a Gram-negative environmental bacterium found in tropical climates that causes melioidosis. Culture remains the diagnostic gold standard, but isolation of *B. pseudomallei* from heavily contaminated sites, such as fecal specimens, can be difficult. We recently reported that *B. pseudomallei* is capable of infecting the gastrointestinal tract of mice and suggested that the same may be true in humans. Thus, there is a strong need for new culture techniques to allow for efficient detection of *B. pseudomallei* in fecal and other specimens. We found that the addition of norfloxacin, ampicillin, and polymyxin B to Ashdown’s medium (NAP-A) resulted in increased specificity without affecting the growth of 25 *B. pseudomallei* strains. Furthermore, recovery of *B. pseudomallei* from human clinical specimens was not affected by the three additional antibiotics. Therefore, we conclude that NAP-A medium provides a new tool for more sensitive isolation of *B. pseudomallei* from heavily contaminated sites.

INTRODUCTION

*Burkholderia pseudomallei* is a saprophytic bacterium present in soil and surface water that causes melioidosis in humans and animals. Major endemic areas include southeast Asia and northern Australia, although as diagnostic facilities improve, the bacterium has been isolated from additional countries in tropical and subtropical latitudes. Melioidosis can be an acutely fatal disease, with many patients succumbing shortly after clinical presentation, although long latency periods of up to 62 years have been reported. Infection is thought to occur after inoculation, inhalation, or ingestion, although the contribution of each route is not fully understood. Symptoms are highly protean, and proper diagnosis is critical, because timely administration of appropriate antibiotics is important for clearance of *B. pseudomallei*. Culture remains the gold standard for diagnosis, and although *B. pseudomallei* can grow on most common laboratory media, isolation from non-sterile sites requires the use of selective media.

A number of selective media have been developed for *B. pseudomallei*, although the selective medium that has been shown to provide the best combination of sensitivity and specificity for isolation of *B. pseudomallei* is Ashdown’s medium (ASH). ASH contains crystal violet and gentamicin as selective components as well as glycerol and neutral red to allow for differentiation based on colony morphology. Multiple modifications of ASH and other selective media have been developed using different antibiotics, including colistin (polymyxin E), polymyxin B, chloramphenicol, vancomycin, penicillin, ampicillin, streptomycin, amikacin, and increased gentamicin concentrations to improve specificity. Although some media formulations have included multiple antibiotics, most have used a single antibiotic to improve selectivity. Moreover, to our knowledge, fluoroquinolones have not yet been investigated as an additive to selective medium for *B. pseudomallei*.

Intrinsic antibiotic resistance is a hallmark of *B. pseudomallei*. For instance, numerous antibiotics belonging to different classes are extruded from the cell by resistance nodulating cell division (RND) efflux pumps. For example, AmrAB-OprA is responsible for the intrinsic aminoglycoside and macrolide resistance observed with most *B. pseudomallei* strains. In strain KHW, BpeAB-OprA was also shown to efflux aminoglycosides, but this finding was not corroborated by studies with strain 1026b, where this pump was shown to confer low-level chloramphenicol, fluoroquinolone, macrolide, and tetracycline resistance but not extrude aminoglycosides. Certain fluoroquinolones have also been shown to be effluxed (T. Mima and others, unpublished observations), and other studies have shown that alterations in DNA gyrase can lead to resistance. In addition, the *B. pseudomallei* genome encodes seven putative Ambler class A, B, and D β-lactamases. Of these β-lactamases, only the PenA class A β-lactamase has been shown to confer clinically significant β-lactam resistance. Finally, the cell envelope structure, notably lipopolysaccharide, is known to be responsible for resistance to cationic peptides, such as polymyxin. Although significant levels of antibiotic resistance are a major challenge in treating patients with melioidosis, these *Burkholderia* traits provide options for development of selective media.

Selective media have improved *B. pseudomallei* isolation rates, although *B. pseudomallei* recovery from certain sites can still be challenging. For instance, although *B. pseudomallei* has been isolated from rectal swabs of melioidosis patients, overgrowth of enteric bacteria was also reported. Therefore, we investigated the ability of the addition of norfloxacin, ampicillin, and polymyxin B to improve the specificity of ASH for recovery of *B. pseudomallei* from clinical specimens. These antibiotics were chosen because of their previous use in *B. pseudomallei*-selective media (ampicillin and polymyxins), intrinsic resistance among *B. pseudomallei* isolates (norfloxacin, ampicillin, and polymyxins), and previous use against enteric flora (norfloxacin and ampicillin). This report describes the optimization of the new medium norfloxacin, ampicillin, and polymyxin B ASH medium (NAP-A medium). Specificity and sensitivity studies were performed using samples from infected mice. In addition,
a side-by-side comparison of recovery rates using NAP-A and ASH medium was done using human clinical samples.

MATERIALS AND METHODS

Bacterial strains and growth conditions. A detailed description of B. pseudomallei strains used in this study is provided in Table 1. Briefly, B. pseudomallei strains included 12 clinical strains (7 blood, 3 pus, and 2 lung isolates), 10 environmental isolates, and 4 clinical isolates commonly used in laboratory experiments. All B. pseudomallei strains were originally isolated in Thailand, and provided by Sharon Peacock (Mahidol University, Mahidol, Thailand and University of Cambridge, Cambridge, United Kingdom). Routine experiments involving B. pseudomallei were performed with strain 1026b, a strain isolated from the blood of a melioidosis patient in Thailand.34 Other B. pseudomallei isolates, B. thailandensis strains, and additional Burkholderia spp. strains are described in Table 1.

Freezer stocks of all bacterial strains were prepared from stationary phase Luria–Bertani (LB) broth (BD Biosciences, San Jose, CA) cultures grown at 37°C with shaking at 250 rpm. Sterile glycerol (Fisher Scientific, Pittsburgh, PA) was added to each culture at a 20% (vol/vol) final concentration, and glycerol stocks were frozen at −80°C. Unless noted, plating of pure bacterial cultures was performed using bacteria thawed directly from freezer stocks. In experiments where overnight cultures were used, cultures were grown in LB broth at 37°C with shaking at 250 rpm, and stationary phase cultures were used for plating. All procedures involving B. pseudomallei performed at Colorado State University were performed in a Biosafety Level 3 (BSL3) facility in accordance with approved BSL3 and Select Agent protocols.

Mice and animal infections. Female BALB/c and C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME). Male and female Institute for Cancer Research (ICR) mice were purchased from Harlan Laboratories (Indianapolis, IN). All mice used in experiments were housed under pathogen-free conditions in microisolator cages, and mice were 12–20 weeks of age at the time of infection. Oral (p.o.) and intranasal (i.n.) infection of mice with B. pseudomallei was performed as described previously.35 Immediately before animal inoculation, bacterial stocks frozen in LB broth with 20% glycerol were thawed and diluted in sterile phosphate buffered saline (PBS; Sigma-Aldrich, St. Louis, MO). Infectious doses were determined by plating serial dilutions of each inoculum on LB agar (BD Biosciences, San Jose, CA). Oral inoculations were performed with a stainless steel 22-gauge gavage needle, and mice were inoculated in a total volume of 100 μL. For i.n. inoculation, mice were anesthetized with intraperitoneal (i.p.) injection of ketamine (100 mg/kg; Pfizer, New York, NY) and xylazine (10 mg/kg; Lloyd Laboratories, Shenandoah, IA), and inoculations were done using in a total volume of 20 μL (10 μL per nostril). Median lethal dose (LD₅₀) values for acute disease (i.e., euthanasia required on or before day 7) in BALB/c mice were previously determined to be 1.04 × 10⁷ cfu for p.o. infection and 9 × 10⁷ cfu for i.n. infection with B. pseudomallei strain 1026b.35 All experiments involving animals were approved by the Institutional Animal Care and Use Committee at Colorado State University and performed in accordance with the National Institutes of Health guidelines for the humane use of laboratory animals.

Antibiotic preparation and storage. Gentamicin was purchased as a pre-made solution in deionized water (10 mg/mL). Norfloxacin powder was dissolved at a concentration of 100 mg/mL in glacial acetic acid and then diluted to a final concentration of 10 mg/mL with PBS. Based on previous studies showing that low pH buffers increase the stability of ampicillin, ampicillin powder was dissolved in 0.1 M acetate buffer (pH 6) at a concentration of 50 mg/mL.36 Polymyxin B powder was dissolved in deionized water at a concentration of 2.5 × 10⁴ units/mL. Vancomycin powder was dissolved in deionized water at 0.5 mg/mL. Rifampicin powder was dissolved in dimethyl sulfoxide at 50 mg/mL. Fosfomycin powder was dissolved in deionized water at 50 mg/mL. All reagents were purchased from Sigma-Aldrich (St. Louis, MO).

Table 1. Bacterial strains

| Strain | Source | Type | Strain Source | Type | Strain Source | Type |
|--------|--------|------|---------------|------|---------------|------|
| 2613a  | Blood  | Thailand | E0008 | Blood | Thailand | E264 |
| 2650a  | Blood  | Thailand | E0031 | Blood | Thailand | E421 |
| 2668a  | Blood  | Thailand | E0037 | Blood | Thailand | E426 |
| 2674a  | Blood  | Thailand | E0237 | Blood | Thailand | E426 |
| 2692a  | Blood  | Thailand | E0342 | Blood | Thailand | E426 |
| 2704a  | Blood  | Thailand | E0356 | Blood | Thailand | E426 |
| 2671a  | Pus     | Thailand | E0377 | Pus   | Thailand | E0383 |
| 2617a  | Pus     | Thailand | E0383 | Pus   | Thailand | E0386 |
| 2618a  | Pus     | Thailand | E0386 | Pus   | Thailand | E0394 |
| 2685a  | Pus     | Thailand | E0394 | Pus   | Thailand | E0394 |
| 2670a  | Lung    | Thailand | E0394 | Lung  | Thailand | E0394 |
| 2719a  | Lung    | Thailand | E0394 | Lung  | Thailand | E0394 |
| 1026b  | Blood   | Thailand | E0394 | Blood | Thailand | E0394 |
| K96243 | Human   | Thailand | E0394 | Human | Thailand | E0394 |
| 1710b  | Blood   | Thailand | E0394 | Blood | Thailand | E0394 |
| 1106b  | Pus     | Thailand | E0394 | Pus   | Thailand | E0394 |

*All Strain isolated from patients in Ubon Ratchatani in northeast Thailand.
†Centers for Disease Control and Prevention.
Gentamicin solutions were stored at 4°C according to the manufacturer’s instructions. Stock solutions of norfloxacin, ampicillin, and polymyxin B were stored at −80°C and used within 6 months as determined by stability experiments performed in the current investigation (see below).

Selective media preparation. Modified trypticase soy agar. Modified trypticase soy agar (MTSA) was prepared as described previously. \(^3\) Briefly, 4% glycerol (Fisher Scientific, Pittsburgh, PA), 5 µg/mL crystal violet (EMD Science, Gibbstown, NJ), and 50 µg/mL neutral red (Sigma-Aldrich, St. Louis, MO) were added to trypticase soy agar (BBL 211043; BD Biosciences, San Jose, CA).

ASH. ASH was also prepared as described previously. \(^8\) Briefly, MTSA was prepared as described above, autoclaved, and cooled to 55°C, and gentamicin was added at a final concentration of 4 µg/mL.

NAPA-A. NAPA-A was prepared by using ASH medium as the basal medium and incorporating three additional antibiotics. MTSA was prepared as described above, autoclaved, and cooled to 55°C, and gentamicin at 4 µg/mL, norfloxacin at 4 µg/mL, ampicillin at 10 µg/mL, and polymyxin B at 300 units/mL were added.

Additional selective media. Norfloxacin, ampicillin, and polymyxin B MTSA (NAP-MTSA) was prepared the same as the NAPA medium described above, although gentamicin was not added. LB agar with gentamicin, norfloxacin, ampicillin, and polymyxin B was also prepared by autoclaving LB agar, cooling the media to 55°C, and adding gentamicin at 4 µg/mL, norfloxacin at 4 µg/mL, ampicillin at 10 µg/mL, and polymyxin B at 300 units/mL.

Fecal pellet collection and processing. Fecal pellets were collected from mice and processed as described previously. \(^3\) Briefly, mice were transferred into small plastic containers, and fecal pellets were then collected from these containers. Fecal pellets were resuspended in PBS at a concentration of 0.1 g feces/mL PBS and homogenized using a Stomacher 80 Biomaster (Seward, Port Saint Lucie, FL). Serial dilutions of fecal homogenates were prepared in sterile PBS and plated on agar plates. The lower limit of bacterial detection in feces was 10–60 cfu/g feces.

Optimization of norfloxacin, ampicillin, and polymyxin B concentrations. Based on previous reports showing that ASH medium provides the best combination of specificity and sensitivity, the ability of additional antibiotics to improve the specificity of ASH was investigated. \(^9,10\) Optimized concentrations of norfloxacin, ampicillin, and polymyxin B were determined using 10 different enteric bacteria colony types that were routinely cultured from murine gastrointestinal (GI) tissues plated on ASH (isolates were not identified on a genus or species level). These 10 isolates were subcultured onto ASH medium supplemented with different concentrations of each antibiotic. Several different concentrations of all three antibiotics were evaluated for their ability to suppress endogenous flora. To determine if enteric bacteria capable of growing in the presence of gentamicin would be susceptible to a different antibiotic in the same class, streptomycin was investigated at 10 µg/mL. \(^3\)

Determination of organ bacterial burden. Bacterial burden in organ homogenates was quantitated as described previously. \(^3\) Mice were euthanized, and organs were placed in 4 mL sterile PBS. Before homogenization, the stomach and cecum were cut into ~1- to 2-cm² sections, and small intestine and colon tissues were cut open longitudinally and then cut into 2- to 3-cm lengths. Organs were homogenized using a Stomacher 80 Biomaster, and serial 10-fold dilutions of organ homogenates were prepared in sterile PBS. Organ homogenates and serial dilutions were plated on LB, ASH, or NAPA agar plates. Unless noted, agar plates were incubated at 37°C, and colonies were counted at 48 hours. The limit of detection in organ homogenates was 20 cfu/organ.

Clinical evaluation. To assess the use of NAPA medium to isolate *B. pseudomallei* from human clinical samples, the medium was compared with ASH in a small-scale evaluation in a diagnostic laboratory in an endemic area (Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao People’s Democratic Republic). Clinical samples that were being cultured routinely for *B. pseudomallei* on ASH and in a selective broth based on ASH containing colistimethate (SBCT; 50 mg/L) \(^17\) that was subcultured onto ASH after 48 hours of incubation were also cultured on NAPA plates in parallel. The formulations of media were similar to those formulations described above, except that the local recipe for ASH currently in use was followed. This recipe comprised 10 g Tryptone soya broth (Oxoid, Basingstoke, United Kingdom), 15 g Agar No. 1 (Oxoid, Basingstoke, United Kingdom), 40 mL glycerol (VWR, East Grinstead, United Kingdom), 5 mL 0.1% crystal violet (Merck, Beeoston, United Kingdom), and 5 mL 1% neutral red (Ranark, Faridad, India) per 1 L, to which gentamicin for injection (Bidiphar, Quy Non, Vietnam) was added to give a final concentration of 5 µg/mL. For NAPA medium, norfloxacin, ampicillin, and polymyxin (Sigma-Aldrich, St. Louis, MO) were added to achieve the same final concentrations as listed above. Cultures on ASH were read as usual by the clinical laboratory staff, whereas NAPA cultures were read by another staff member who was blind to the results of ASH cultures. The study was carried out in two phases. During the first phase, the presence or absence of *B. pseudomallei* was recorded qualitatively (i.e., present or absent). During the second phase, the growth of both *B. pseudomallei* and other competing flora on both media was recorded semiquantitatively according to the method by Nye and others. \(^39\)

Stability of antibiotic stock solutions. The Kirby–Bauer disk diffusion method was chosen to investigate the stability of antibiotic stock solutions used in NAPA medium. \(^36,40\) The disk diffusion assay was performed according to the Clinical and Laboratory Standards Institute guidelines. \(^41\) Antibiotic stocks were prepared as described above, aliquoted, and stored at either 4°C or −80°C. At various time points after preparation, an aliquot from each antibiotic was tested for the ability to kill *Escherichia coli* strain DH5α. \(^42\) *E. coli* was grown overnight on Mueller Hinton (MH; BD Biosciences, San Jose, CA) agar plates, and bacterial colonies were resuspended in sterile PBS at a density equivalent to a 0.5 MacFarlane standard. The bacterial suspension was then streaked on an MH agar plate using a sterile swab to create a lawn of bacteria; 6-mm disks (Whatman, Piscataway, NJ) were loaded with the desired amount of antibiotic (gentamicin [10 µg], norfloxacin [10 µg], ampicillin [10 µg], and polymyxin B [300 units]) in a total volume of 25 µL, and disks were allowed to air dry aseptically. \(^43\) Antibiotic loaded disks were added to the MH agar plate containing the *E. coli* lawn, plates were incubated at 37°C, and zones of inhibition were measured after 16–18 hours of growth. At each time point, zone diameters were compared.
with zones determined from the original antibiotic stocks before storage at 4°C or −80°C.

Statistical analysis. Statistical analyses were performed using Prism 5.0 software (Graph Pad, San Diego, CA). Differences in percentages of positive samples were compared using a two-tailed Fisher exact test. Analyses comparing two groups were done using a two-tailed Student t test, and analyses comparing more than two groups were performed using a one-way analysis of variance (ANOVA) followed by a Tukey multiple means comparison test. In experiments comparing two variables, data were analyzed by a two-way ANOVA followed by a Bonferroni post-test. Differences were considered statistically significant for P < 0.05.

RESULTS

While developing a murine model of chronic enteric melioidosis, we observed that enteric bacteria often overgrew B. pseudomallei when cultured on ASH.35 The effects of norfloxacin, ampicillin, and polymyxin B on the growth of enteric bacteria subcultured from ASH are reported in Table 2. Norfloxacin selected against 9 of 10, 8 of 10, and 6 of 10 enteric colonies at concentrations of 10, 5, and 1 μg/mL, respectively (Table 2). We found that 10 μg/mL ampicillin prevented growth of all 10 enteric bacteria isolates. However, increasing the concentration of polymyxin B up to 600 units/mL did not significantly inhibit enteric isolate growth compared with ASH (P = 0.06). Only 3 of 10 enteric bacteria were inhibited by streptomycin, similar to the result with gentamicin.

In summary, these studies showed that 10 or 5 μg/mL norfloxacin or 10 μg/mL ampicillin significantly reduced the growth of enteric bacteria. Increasing polymyxin B provided only minor improvements in selectivity against enteric isolates. Therefore, studies were performed to investigate the ability of B. pseudomallei to grow in the presence of antibiotics capable of inhibiting enteric isolate growth.

B. pseudomallei strain 1026b was serially diluted in PBS and plated on ASH containing each individual antibiotic. We found that neither 10 μg/mL ampicillin nor 300 U/mL polymyxin B affected B. pseudomallei growth. Norfloxacin was tested at 1.5, and 10 μg/mL, and it was further titrated over a 2–10 μg/mL range in 2-μg/mL increments (Table 2) (data not shown). From these studies, 4 μg/mL was consistently identified as the concentration that did not alter B. pseudomallei growth.

Table 2

| Titration of additional antibiotics used in NAP-A medium |
|---------------------------------------------------------|
| Enteric bacteria                                      |
| Medium        | Positive | P value* | B. pseudomallei† |
| ASH           | 9/10     | NA       | 8.85 ± 0.06      |
| ASH + 10 μg/mL Nor        | 1/10     | P = 0.001 | 8.62 ± 0.01      |
| ASH + 5 μg/mL Nor        | 2/10     | P = 0.006 | 8.88 ± 0.03      |
| ASH + 1 μg/mL Nor        | 4/10     | P = 0.06  | 8.69 ± 0.04      |
| ASH + 10 μg/mL Amp       | 0/10     | P = 0.0001 | 8.94 ± 0.08      |
| ASH + 5 μg/mL Amp       | 4/10     | P = 0.06  | ND                |
| ASH + 600 U/mL PxB      | 4/10     | P = 0.06  | ND                |
| ASH + 500 U/mL PxB      | 7/10     | P = 0.58  | ND                |
| ASH + 300 U/mL PxB      | 8/10     | P = 1.0   | 8.80 ± 0.05      |
| ASH + 10 μg/mL Str      | 7/10     | P = 0.58  | ND                |

*Amp = ampicillin; NA = not applicable; ND = not determined; Nor = norfloxacin; PxB = polymyxin B; Str = streptomycin.
*Statistical differences compared with ASH were determined by a two-tailed Fisher exact test.
†B. pseudomallei 1026b titers reported as log_{10} cfu per 1 mL ± SEM.

Figure 1. Effect of individual antibiotics on growth of fecal bacteria. Fecal pellets were homogenized in PBS, and serial dilutions were plated on various agar media. MTSA was supplemented with gentamicin (4 μg/mL), norfloxacin (4 μg/mL), ampicillin (10 μg/mL), or polymyxin B (300 U/mL). Fecal pellets were collected from cages of five mice. Data from BALB/c (N = 15 cages), C57BL/6 (N = 14 cages), and ICR (N = 12 cages) mice were pooled (N = 41 cages). Samples were processed as described in Materials and Methods and plated on each medium. Data are presented as individual log_{10} cfu per 1 g feces, with bars representing the mean titer for each group. Statistical differences between antibiotics were determined by a one-way ANOVA followed by a Tukey multiple means test (***P < 0.001). Data were pooled from seven individual experiments.
were sufficient to consistently inhibit growth of fecal bacteria when used alone. Therefore, we concluded that including all four antibiotics would likely be the most effective formulation for inhibiting the growth of contaminating flora.

**NAP-A medium is more effective at inhibiting enteric bacterial growth.** To access the effectiveness of the new four-antibiotic NAP-A medium, growth of enteric bacteria in both GI tissues and fecal pellets was assessed (Figure 2). We found that use of NAP-A medium resulted in a significant reduction in enteric bacterial growth from BALB/c, C57BL/6, and ICR mice compared with ASH medium. For example, enteric bacteria from GI tissues of BALB/c mice grew on ASH medium, whereas enteric bacterial growth was not observed on the four-antibiotic NAP-A medium (Figure 2). The addition of these four antibiotics to LB media also prevented enteric bacterial growth from fecal pellets of BALB/c and C57BL/6 mice (data not shown). Therefore, the use of four-antibiotic NAP-A medium significantly reduced the growth of enteric bacteria from multiple strains of mice, which was assessed by both qualitative and quantitative assays.

**NAP-A medium improves** *B. pseudomallei* **isolation from samples with low bacterial burdens.** To determine whether *B. pseudomallei* could be isolated from infected GI tissues using NAP-A medium, tissues obtained from BALB/c mice infected p.o. or i.n. individually with each of four different *B. pseudomallei* strains (strain 1026b, 2671a, 2685a, or 2719a) were subjected to bacterial culture; 125 GI tissues (stomach, small intestine (SI), cecum, or colon) were plated in parallel on both ASH and NAP-A media. No significant differences in *B. pseudomallei* titers were observed between samples plated on ASH versus NAP-A medium (P = 0.35; data not shown). These results showed that the three additional antibiotics in NAP-A medium did not affect the ability to isolate *B. pseudomallei* from tissues.

A major effect of NAP-A medium was observed when cultures of undiluted organ homogenates (Figure 2B) were compared with cultures on ASH. Therefore, we next assessed the effect of NAP-A medium on *B. pseudomallei* detection in tissues with very low levels of infection (titer ≤ 1,000 cfu/organ). Of 125 GI samples plated on both NAP-A and ASH, 34 low-titer samples were identified. In the low-titer samples, a significant increase (P = 0.03) in *B. pseudomallei* titers was observed on NAP-A medium (Figure 3). This result is likely caused by the ability of NAP-A medium to prevent the growth of enteric bacteria, which was often observed to overgrow *B. pseudomallei*. Indeed, qualitative examples were also observed in GI tissues from mice infected with *B. pseudomallei* (Figure 3).

The four antibiotics in NAP-A medium did not have an effect on the growth of *B. pseudomallei* strain 1026b (Table 2) (data not shown). However, it was also important to assess the wider ability of NAP-A medium to be used as a general culture medium for multiple *B. pseudomallei* strains. Therefore, 25 additional *B. pseudomallei* strains (12 clinical,
As 10 environmental, and 3 laboratory strains) (Table 1) were assessed for their ability to grow on NAP-A medium. Over-night cultures of each strain were prepared in LB broth, and stationary phase cultures were diluted in sterile PBS and plated on each agar medium. We found nearly equivalent growth of all 25 strains on all three media (LB, ASH, or NAP-A; *P = 0.99) (Figure 3). The growth of additional Burkholderia spp. was also investigated by streaking each strain onto agar media. Growth was equivalent on both media, with *B. thailandensis*, *B. oklahomensis*, *B. dolosa*, and *B. ubonensis* capable of growth on both ASH and NAP-A, whereas neither *B. gladioli* pathovar *cocovenenans* nor *B. vietnamiensis* was able to grow on either medium (data not shown). In summary, the addition of four antibiotics to the NAP-A medium did not reduce recovery of multiple different *B. pseudomallei* strains from infected tissues. In addition, NAP-A medium improved isolation of *B. pseudomallei* from sparsely colonized tissues without suppressing growth of a panel of clinical isolates of *B. pseudomallei*.

Comparison of culture of specimens from suspected human melioidosis patients on ASH and NAP-A medium. Lastly, we compared the effectiveness of NAP-A with conventional ASH medium for recovery of *B. pseudomallei* from clinical specimens from humans with suspected *B. pseudomallei* infection (melioidosis). A total of 359 consecutive clinical specimens (119 pus/pus swab specimens, 172 throat swabs, 2 mouth swabs, 2 sputum specimens, and 64 fluid specimens [31 ascitic, 19 pleural, 5 joint, 2 pericardial, 6 Pouch of Douglas, and 1 gastric aspirate]) obtained from patients in Laos was plated in parallel on ASH medium and NAP-A medium; 16 positive samples were obtained (7 pus/pus swab, 7 throat swabs, 1 ascitic fluid, and 1 pleural fluid), and all 16 samples grew on both ASH and NAP-A medium either on direct plating or through

### Table 3

| Isolation from clinical samples | Total samples | ASH | NAP-A | *P* value* |
|--------------------------------|---------------|-----|-------|------------|
| *B. pseudomallei*              | 359†          | 16  | 16†   | 1.0        |
| Commensal flora                | 150§          | 6   | 0     | 0.014      |

*Growth rates on ASH and NAP-A were compared by a two-tailed Fisher exact test.
†Samples were composed of 119 pus/pus swab, 172 throat swab, 64 fluids, 2 mouth swabs, and 2 sputum samples.
§One sample was not tested by direct plating but positive when plated after broth culture.
¶Samples were composed of 69 throat swab, 48 pus/pus swab, 29 fluids, 2 mouth swabs, and 2 sputum samples.
enrichment (Table 3). One of the samples that was positive by direct plating on ASH was not tested by direct plating onto NAP-A agar in error, but it was positive when broth enrichment cultures were plated on NAP-A medium. In contrast, there was one sample that was positive by direct plating on NAP-A but negative on direct plating on ASH, although B. pseudomallei was isolated after SBCT enrichment on both media. In general, the NAP-A and ASH plates were read as positive on the same day of incubation, with the exception of one each that was read as positive on ASH and NAP-A 24 hours earlier than the other medium. During the second phase, there were no differences seen between the semiquantitative growth of B. pseudomallei colonies from each sample on the two media (data not shown). These results showed, therefore, that B. pseudomallei was recovered from patient specimens equivalently when grown on either ASH or NAP-A media (P = 1.0).

In the second phase, the ability of NAP-A medium to suppress growth of commensal bacteria in human clinical specimens was assessed by semiquantitatively comparing growth of contaminating bacteria on NAP-A and ASH plates using a previously described technique. Growth of contaminating flora was investigated in a total of 150 samples (48 pus/pus swab specimens, 69 throat swabs, 29 fluid specimens, 2 mouth swabs, and 2 sputum specimens). Contaminating flora growth was not observed on NAP-A medium, whereas six samples (four throat swabs and two pus samples) grew contaminating flora on ASH medium (two samples on direct culture and all six samples on SBCT subculture). One specimen had 1–10 colonies, one specimen had >50 colonies on the direct culture, two specimens had 10–50 colonies, and four specimens had >50 colonies on SBCT subculture. Statistical comparison of the overall frequency of contaminating growth on the two media (Fisher exact test) revealed a significant reduction in the isolation of contaminating flora on NAP-A medium compared with ASH (Table 3) (P = 0.014).

**Stability of NAP-A medium.** The stability of NAP-A medium constituent antibiotic solutions was investigated using the disk diffusion method. These studies showed that gentamicin, norfloxacin, and ampicillin stock solutions were stable for 6 months when stored at −80°C, whereas polymyxin B was stable for 3 months (Figure 4). At 4°C, gentamicin and norfloxacin remained stable for at least 6 months, whereas polymyxin B was stable for 3 months. A small but significant reduction in polymyxin B stability was observed after 3 months of storage at 4°C or −80°C, although a high degree of stability was still observed at 6 months. In contrast, ampicillin was only stable for 2 weeks at 4°C (Figure 4).

The stability of NAP-A plates was investigated by using fecal bacteria to screen the stability of NAP-A medium compared with ASH medium after storage at 4°C. After 6 months of storage at 4°C, enteric bacteria from BALB/c mice was unable to grow on NAP-A medium (limit of detection = 10 cfu/g), whereas an average titer of 2.5 log₁₀ cfu/g was isolated when the same samples were plated on 6-month ASH medium (Figure 4). However, the stability of NAP-A medium declined by 9 months of storage at 4°C (Figure 4). However, the 9-month NAP-A enteric bacterial titer was still significantly less than the enteric bacterial titer on ASH medium (P < 0.001). In summary, NAP-A medium remained stable for at least 6 months when stored at 4°C, and stock solutions of antibiotics used to prepare NAP-A medium could also be stored for at least 6 months at −80°C.

**DISCUSSION**

In this report, we describe the development and clinical evaluation of a modified ASH medium (NAP-A) designed to suppress growth of commensal and contaminating bacteria in clinical specimens, while still allowing the growth of B. pseudomallei, even when present in very low numbers. We found that addition of norfloxacin, ampicillin, and polymyxin B to conventional ASH medium resulted in increased specificity...
and sensitivity for isolation of \textit{B. pseudomallei} from GI tissues of mice. Moreover, NAP-A was comparable with ASH in recovery of \textit{B. pseudomallei} from human clinical specimens, while still effectively suppressing growth of contaminating bacterial flora. In addition, NAP-A medium did not suppress the growth of 25 different clinical isolates of \textit{B. pseudomallei}. These results suggest, therefore, that NAP-A medium may be a suitable alternative to ASH medium for isolation of \textit{B. pseudomallei} from clinical specimens with high levels of contamination with endogenous flora, such as gastrointestinal specimens.

Although the oral route of infection with \textit{B. pseudomallei} in humans has received relatively little attention, there is growing epidemiological and clinical evidence that oral infection may be a primary route of \textit{B. pseudomallei} infection. For example, culture-positive drinking water and breast milk have been associated with melioidosis cases, including two separate outbreaks in Australia and a case of infant melioidosis.\textsuperscript{46–47} In addition, ulcers have been reported in the stomach, small intestine, and colon of melioidosis patients, and \textit{B. pseudomallei} has been isolated from gastric fluids, intestinal contents, and rectal swabs of melioidosis patients.\textsuperscript{48–53} Moreover, two mouse models of melioidosis have recently shown that oral infection results in persistent colonization of the stomach together with fecal shedding and dissemination to extraintestinal organs.\textsuperscript{54,55} Our studies in the murine model of chronic GI infection also indicated that murine enteric bacteria often outcompeted \textit{B. pseudomallei} when grown on ASH. Thus, we reasoned that overgrowth of enteric bacteria on ASH would also likely complicate investigation of enteric \textit{B. pseudomallei} infection in humans. Until truly effective selective media for culture of \textit{B. pseudomallei} from GI and fecal samples are developed, the true prevalence of GI infection with \textit{B. pseudomallei} in humans cannot be determined. Thus, the new NAP-A medium may be particularly useful as a means to begin to assess GI chronic infection with \textit{B. pseudomallei}.

Although the current study used ASH as the basal medium, other selective media have been developed for specific isolation of \textit{B. pseudomallei}. For example, \textit{B. pseudomallei} selective agar (BPSA) has been reported to improve isolation of mucoid colonies of \textit{B. pseudomallei}, whereas growth of these mucoid colonies has been reported to be inhibited on ASH.\textsuperscript{55} In one clinical study, however, BPSA medium was found to be equivalent to ASH in its ability to grow \textit{B. pseudomallei} but also found to be less selective.\textsuperscript{10} Additional studies may be warranted to determine whether the addition of norfloxacin, ampicillin, and polymyxin B would improve the selectivity of BPSA medium.

NAP-A medium may also improve isolation of \textit{B. pseudomallei} from environmental specimens, such as soil or water, by suppressing growth of the environmental microbiota. Although ASH and a basal salt solution supplemented with threonine have been used successfully for the isolation of \textit{B. pseudomallei} from soil and water, contaminating bacteria often complicate environmental studies.\textsuperscript{56,57} Larger volumes of soil could potentially be processed, allowing for more readily performed quantitative analyses and a reduced need for initial broth culture. Indeed, studies in Laos are currently underway to determine whether NAP-A medium could improve isolation of \textit{B. pseudomallei} from soil samples.

In summary, culturing heavily contaminated specimens on NAP-A medium resulted in more effective recovery of isolation of \textit{B. pseudomallei} from fecal specimens of mice, whereas recovery of \textit{B. pseudomallei} from human clinical specimens was equivalent between ASH and NAP-A medium. We also determined that NAP-A medium and antibiotic stock solutions could be stored for extended periods without loss of activity. Although only a small-scale study comparing clinical \textit{B. pseudomallei} isolation with ASH or NAP-A was performed, the success of these studies warrants additional investigation of NAP-A medium for recovery of \textit{B. pseudomallei} from wound and fecal specimens of melioidosis patients as well as environmental specimens.

Received March 5, 2013. Accepted for publication June 30, 2013.

Acknowledgments: The authors thank Prof. Sharon Peacock for providing the \textit{B. pseudomallei} strains used in these studies. We also thank Dr. Katie Propst for her assistance with animal studies. The clinical evaluation was carried out as part of the program of the Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit funded by the Wellcome Trust of Great Britain. We are grateful to all of the staff of the Microbiology Laboratory, Mahosot Hospital, Vientiane, Laos, who assisted with the laboratory studies; Laboratory Director Dr. Rattanaphone Phetsouvanh; the hospital directors; and the Minister of Health and the Director of the Curative Department, Ministry of Health, for their support.

Financial support: This work was supported by National Institutes of Health—National Institute of Allergy and Infectious Diseases Grants R21AI091991 and AI065357.

Authors’ addresses: Andrew Goodyear, Linda Strange, Herbert P. Schweizer, and Steven Dow, Department of Microbiology, Immunology, and Pathology, Rocky Mountain Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research, Colorado State University, Fort Collins, CO, E-mails: goody13@colostate.edu, lindamariestrange@gmail.com, Herbert.Schweizer@ColoState.edu, and sdow@colostate.edu. Drew A. Rholl, Department of Biology, North Park University, Chicago, IL, E-mail: drewrholl@gmail.com. Joy Silisouk and David A. B. Dance, Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit. Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao People’s Democratic Republic. E-mails: joy@tropmedres.ac and david.d@tropmedres.ac.

REFERENCES

1. Limmathurotsakul D, Peacock SJ, 2011. Melioidosis: a clinical overview. Br Med Bull 99: 125–139.
2. Currie BJ, Dance DAB, Cheng AC, 2008. The global distribution of \textit{Burkholderia pseudomallei} and melioidosis: an update. Trans R Soc Trop Med Hyg 102: S1–S4.
3. Currie BJ, Ward L, Cheng AC, 2010. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 Year Darwin Prospective Study. PLoS Negl Trop Dis 4: e900.
4. Ngany V, Lemeshev Y, Sadikowski L, Crawford G, 2005. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol 43: 970–972.
5. Chaowagul W, Simpson AJ, Suputtamongkol Y, White NJ, 1999. Empirical cefepime treatment of melioidosis. Clin Infect Dis 28: 1328.
6. Loveeena, Chaudhry R, Dhawan B, 2004. Melioidosis; the remarkable imitator: recent perspectives. J Assoc Physicians India 52: 417–420.
7. Poe RH, Vassallo CL, Domm BM, 1971. Melioidosis: the remarkable imitator. Am Rev Respir Dis 104: 427–431.
8. Ashdown LR, 1979. An improved screening technique for isolation of \textit{Pseudomonas pseudomallei} from clinical specimens. Pathology (Phila) 11: 293–297.
9. Glass MB, Bcesley CA, Wilkins PP, Hoffmaster AR, 2009. Comparison of four selective media for the isolation of \textit{Burkholderia mallei} and \textit{Burkholderia pseudomallei}. Am J Trop Med Hyg 80: 1023–1028.
10. Peacock SJ, Chieng G, Cheng AC, Dance DAB, Amornchai P, Wongsvan G, Teerawatthanakorn N, Chierakul W, Day NPJ, Wuthiekanun V. 2005. Comparison of Ashdown’s medium, Burkholderia cepacia medium, and Burkholderia pseudomallei selective agar for clinical isolation of Burkholderia pseudomallei. J Clin Microbiol 43: 5359–5361.

11. Thomas AD, 1977. The isolation of Pseudomonas pseudomallei from soil in north Queensland. Aust Vet J 53: 408.

12. Smith MD, Wuthiekanun V, Walsh AL, White NJ, 1995. Quantitative recovery of Burkholderia pseudomallei from soil in Thailand. Trans R Soc Trop Med Hyg 89: 486–490.

13. Miller WR, Pannell L, Cravill L, Tantong WA, Ingalls MS, 1948. Studies on certain biological characteristics of Malleomyces mallei and Malleomyces pseudomallei: I. morphology, cultivation, viability, and isolation from contaminated specimens. J Bacteriol 53: 115–126.

14. Farkas-Himsley H. 1968. Selection and rapid identification of Pseudomonas pseudomallei from other gram-negative bacteria. Am J Clin Pathol 49: 850–856.

15. Brundage WG, Thuss CJJ, Walden DC, 1968. Four fatal cases of melioidosis in U. S. soldiers in Vietnam. Bacteriologic and pathologic characteristics. Am J Trop Med Hyg 17: 183–191.

16. So SY, Chau PY, Leung YK, Lam WK, Yu DY, 1983. Successful treatment of melioidosis caused by a multiresistant strain in an immunocompromised host with third generation cephalosporins. Am Rev Respir Dis 127: 650–654.

17. Wuthiekanun V, Smith MD, Dance DAB, White NJ, 1995. Isolation of Pseudomonas pseudomallei from soil in northeastern Thailand. Trans R Soc Trop Med Hyg 89: 41–43.

18. Trunck LA, Propst KL, Wuthiekanun V, Tuunyak, A. Beckstrom-Sternberg SM, Beckstrom-Sternberg JS, Peacock SJ, Keim P, Dow SW, Schweizer HP, 2009. Molecular basis of rare aminoglycoside susceptibility and pathogenesis of Burkholderia pseudomallei clinical isolates from Thailand. PLoS Negl Trop Dis 3: e519.

19. Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE, 1999. Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob Agents Chemother 43: 465–470.

20. Chan YY, Tan TM, Ong YM, Chua KL, 2004. BpeAB-OpbR, a multidrug efflux pump in Burkholderia pseudomallei. Antimicrob Agents Chemother 48: 1128–1135.

21. Mima T, Schweizer HP. 2010. The BpeAB-OpbR efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. Antimicrob Agents Chemother 54: 3113–3120.

22. Viktorov DV, Zakharova IB, Podshivalova MV, Kalinkina EV, Merzinova OA, Ageeva NV, Ivanova LF, Alekseev VV. 2008. High-level resistance to fluoroquinolones and cephalosporins in Burkholderia pseudomallei and closely related species. Trans R Soc Trop Med Hyg 102 (Suppl 1): S103–S110.

23. Keith KE, Oyston PC, Crossett B, Fairweather NF, Tibball RW, Walsh TR, Brown KA. 2005. Functional characterization of OXA-57, a class D β-Lactamase from Burkholderia pseudomallei. Antimicrob Agents Chemother 49: 1639–1641.

24. Rholl DA, Papp-Wallace KM, Tomaras AP, Vasil ML, Bonomo RA, Schweizer HP. 2011. Molecular investigations of PenA-mediated β-lactam resistance in Burkholderia pseudomallei. Front Microbiol 2: 139.

25. Livermore DM, Chau PY, Wong AI, Leung YK, 1987. β-Lactamase of Pseudomonas pseudomallei and its contribution to antibiotic resistance. J Antimicrob Chemother 20: 313–321.

26. Holden MTG, Tibball RW, Peacock SJ, Cerdenio-Tarraga AM, Atkins I, Crossman LC, Pitt T, Churcher C, Mungall K, Bentley SD, Sebaihia M, Thomason NR, Basom N, Beuchain IR, Brooks K, Brown KA, Brown NF, Challis GL, Cherevach I, Chillingworth T, Cronin A, Crossett B, Davis P, DeShazer D, Fellwell T, Fraser A, Hance Z, Hauser H, Holroyd S, Jagels K, Keith KE, Maddison M, Moule S, Price C, Quail MA, Rabinowitsch E, Rutherford K, Sanders M, Simmonds M, Songtivilai S, Stevens K, Tumapa S, Vesaratchavest M, Whitehead S, Yeats C, Barrett BC, Oyston P, Parkhill J. 2004. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci USA 101: 14240–14245.

27. Burntnick MN, Woods DE, 1999. Isolation of polymyxin b-susceptible mutants of Burkholderia pseudomallei and molecular characterization of genetic loci involved in polymyxin b resistance. Antimicrob Agents Chemother 43: 204–205.

28. Wuthiekanun V, Dance DA, Wattanagoon Y, Supputtamongkol Y, Chaowagul W, White NJ. 1990. The use of selective media for the isolation of Pseudomonas pseudomallei in clinical practice. J Med Microbiol 33: 121–126.

29. Dannenberg AMJ, Scott EM, 1958. Melioidosis: pathogenesis and immunity in mice and hamsters. II. Studies with avirulent strains of Malleomyces pseudomallei. Am J Pathol 34: 1099–1121.

30. Eckhoff TC, Bennett JV, Hayes PS, Feeley J, 1970. Pseudomonas pseudomallei: susceptibility to chemotherapeutic agents. J Infect Dis 121: 95–102.

31. Dance DA, Wuthiekanun V, Chaowagul W, White NJ, 1989. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother 24: 295–309.

32. Thibaut FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD, 2004. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. Antimicrob Agents Chemother 48: 1134–1138.

33. Membrez M, Blancheur F, Jaquet M, Bibiloni R, Cani PD, Perlini P, Sonck. 2001. Persistent gastric colonization with Burkholderia pseudomallei and dissemination from the gastrointestinal tract following mucosal inoculation of mice. PLoS One 7: e37324.

34. Hwang JM, Piccinini TE, Lameli CJ, Hadley WK, Brooks GF. 1986. Effect of storage temperature and pH on the stability of antimicrobial agents in MIC trays. J Clin Microbiol 23: 959–961.

35. Ivashkiv E, 1973. Ampicillin. Florey K, Brewer GA, eds. Analytical Profiles Drug Substances. New York: Academic Press, 1–61.

36. Al-Izzi SA, Al-Bansam LS, 1989. In vitro susceptibility of Pseudomonas mallei to antimicrobial agents. Comp Immunol Microbiol Infect Dis 12: 5–8.

37. Nye KJ, Fallon D, Frosh dad, Gee B, Graham C, Howe S, Messer S, Turner T, Warren RE, 2002. An evaluation of the performance of XLD, DCA, MLCB, and ABC agars as direct plating media for the isolation of Salmonella enterica from human faeces. J Clin Pathol 55: 286–295.

38. Bauer AW, Kirby WM, Sherris JC, Turck M. 1966. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 45: 493–496.

39. Wiker MA, Cockerill FR, Bush K, Dudley MN, Eliopoulos GM, Hardy DJ, Hecht DW, Hindler JF, Patel WB, Powell M, Turnidge JD, Weinseth MP, Zimmer BL, Ferraro MJ, Swenson JM. 2009. Performance standards for antimicrobial disk susceptibility tests; approved standard. Clin Lab Standards Institute 29: 1–53.

40. Liss LR, 1987. New M13 host: DH5α competent cells. FOCUS 9: 13.

41. Romero CD, Chopin SF, Buck G, Martinez E, Garcia M, Bixby L, 2005. Antibacterial properties of some common herbal remedies of the Southwest. J Ethnopharmacol 99: 253–257.

42. Currie BJ, Mayo M, Anstey NM, Donohoe P, Haase A, Kemp DJ, 2001. A cluster of melioidosis cases from an endemic region is clonal and is linked to the water supply using molecular typing of Burkholderia pseudomallei isolates. Am J Trop Med Hyg 65: 650–654.

43. Inglis TJJ, Garrow SC, Adams C, Henderson M, Mayo M, 1998. Dry-season outbreak of melioidosis in Western Australia. Lancet 352: 1600.

44. Cottew GS, Sutherland AK, Meehan JF, 1952. Melioidosis in sheep in Queensland. Description of an outbreak. Aust Vet J 28: 113–123.

45. Ralph A, McBride J, Currie BJ, 2004. Transmission of Burkholderia pseudomallei via breast milk in Northern Australia. Pediatr Infect Dis J 23: 1169–1171.
48. Stanton AT, Fletcher W, 1925. Melioidosis, a disease of rodents communicable to man. *Lancet* 205:10–13.
49. Heng BH, Goh KT, Yap EH, Loh H, Yeo M, 1998. Epidemiological surveillance of melioidosis in Singapore. *Ann Acad Med Singapore* 27:478–484.
50. Puthucheary SD, Lin HP, Yap PK, 1981. Acute septicemic melioidosis: a report of seven cases. *Trop Geogr Med* 33:19–22.
51. Paton JPT, Peck CR, Van De Schaaf A, 1947. Report on a case of melioidosis from Siam. *BMJ* 1:336–337.
52. Currie BJ, Fisher DA, Howard DM, Burrow JNC, Selvanayagam S, Snelling PL, Anstey NM, Mayo MJ, 2000. The epidemiology of melioidosis in Australia and Papua New Guinea. *Acta Trop* 74:121–127.
53. Jayanetra P, Pipatanagul S, Punyagupta S, Ratanabanangkoon K, Varavithya W, 1974. *Pseudomonas pseudomallei*: 1. Infection in Thailand. *Southeast Asian J Trop Med Public Health* 5:487–491.
54. West TE, Myers ND, Limmathurotsakul D, Liggitt HD, Chantratita N, Peacock SJ, Skerrett SJ, 2010. Pathogenicity of high-dose enteral inoculation of *Burkholderia pseudomallei* to mice. *Am J Trop Med Hyg* 83:1066–1069.
55. Howard K, Inglis TJ, 2003. Novel selective medium for isolation of *Burkholderia pseudomallei* J Clin Microbiol 41: 3312–3316.
56. Galimand M, Dodin A, 1982. Focus on melioidosis throughout the world. *Bull Soc Pathol Exot* 75:375–383.
57. Brook MD, Currie B, Desmarchelier PM, 1997. Isolation and identification of *Burkholderia pseudomallei* from soil using selective culture techniques and the polymerase chain reaction. *J Appl Microbiol* 82:589–596.
58. Tuanyok A, Leadem BR, Auerbach RK, Beckstrom-Sternberg SM, Beckstrom-Sternberg JS, Mayo M, Wuthickanan V, Brettin TS, Nierman WC, Peacock SJ, Currie BJ, Wagner DM, Keim P, 2008. Genomic islands from five strains of *Burkholderia pseudomallei*. *BMC Genomics* 9:566.
59. Harkins DM, DeShazer D, Woods DE, Brinkac LM, Brown KA, Hung GC, Tuanyok A, Zhang B, Nierman WC, 2009. *Burkholderia pseudomallei* 1106b Chromosome I, Whole Genome Shotgun Sequence. Available at: http://www.ncbi.nlm.nih.gov/nuccore/CM000774.1. Accessed December 16, 2010.
60. Glass MB, Steigerwalt AG, Jordan JG, Wilkins PP, Gee JE, 2006. *Burkholderia oklahomensis* sp. nov., a *Burkholderia pseudomallei*-like species formerly known as the Oklahoma Strain of *Pseudomonas pseudomallei*. *Int J Syst Evol Microbiol* 56:2171–2176.
61. Zhao N, Qu C, Wang E, Chen W, 1995. Phylogenetic evidence for the transfer of *Pseudomonas cocovenenans* (van Damme et al. 1960) to the genus *Burkholderia* as *Burkholderia cocovenenans* (van Damme et al. 1960) comb. nov. *Int J Syst Bacteriol* 45:600–603.
62. Coenye T, LiPuma JJ, Henry D, Hoste B, Vandemeulebroecke K, Gillis M, Speert DP, Vandamme P, 2001. *Burkholderia cepacia* genomovar VI, a new member of the *Burkholderia cepacia* complex isolated from cystic fibrosis patients. *Int J Syst Evol Microbiol* 51:271–279.
63. Marshall K, Shakya S, Greenhill AR, Padill G, Baker A, Warner JM, 2010. Antibiosis of *Burkholderia ubonensis* against *Burkholderia pseudomallei*, the causative agent for melioidosis. *Southeast Asian J Trop Med Public Health* 41:904–912.